Uro-Vaxom, capsules 6 mg 90 pcs

Pharmacological group: Immunostimulant.

Pharmacological properties:

Immunopharmacological studies have shown that Uro-Vaksom has the following action: – stimulates T-lymphocytes; – induces formation of endogenous interferon; – increases the content of IgA, including in urine.

Clinical studies have shown that Uro-Vaxom reduces the frequency of recurrent urinary tract infections, especially cystitis.

Indications

Combined treatment and prevention of relapses of chronic urinary tract infections, especially cystitis, regardless of the nature of the microorganism, in combination with antibiotics or antiseptics from 4 years of age.

Pharmacological effect

Pharmacological group: Immunostimulating agent.

Pharmacological properties:

Immunopharmacological studies have shown that Uro-Vaxom has the following effects: – stimulates T-lymphocytes; – induces the formation of endogenous interferon; – increases the content of IgA, including in urine.

Clinical studies have shown that Uro-Vaxom reduces the frequency of relapses of urinary tract infections, especially cystitis.

Active ingredient

Escherichia coli bacteria lysate

Composition

Active substance:

1 capsule contains: 6 mg of lyophilized bacterial lysate of 18 strains of Escherichia coli.

Excipients:

Propyl gallate, sodium glutamate, mannitol, pregelatinized starch, magnesium stearate, dyes (E 171, E 172), gelatin.

Pregnancy

Animal reproduction studies have shown no risk to the fetus, but no controlled studies have been conducted in pregnant women. With regard to breastfeeding, special studies have not been conducted and information on this issue is still not available.

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

Individuals may experience minor gastrointestinal (diarrhea, nausea, vomiting), skin disorders (pruritus, exanthema, erythema) and limited allergic skin reactions.

Rarely: slight fever. In case of more severe complications, treatment should be stopped and consult with your doctor.

Interaction

Interactions with other drugs have not been established to date. As a precaution, the drug should not be used two weeks before and two weeks after ingestion of live vaccines. Immunosuppressive drugs may affect the effect of the drug.

Overdose

There are no data on cases of overdose. The nature of Uro-Vaxom and the results of toxicity studies in animals indicate that overdose is unlikely.

Manufacturer

OM Pharma, Switzerland